Rinzimetostat May Limit Prostate Cancer Lineage Plasticity and Restore Therapeutic Targets

/in /by

New preclinical and translational findings presented at ESMO 2026 suggest that rinzimetostat (ORIC-944), an experimental epigenetic therapy, may help prevent prostate cancer cells from changing their identity to escape androgen receptor (AR)-targeted treatments. Rinzimetostat inhibits the PRC2 complex through its EED subunit. PRC2 regulates gene expression and contributes to lineage plasticity, a process through which […]

Read more

New PSMA Radiohybrid Combines PET Imaging With Alpha Therapy

/in /by

A new preclinical study published in the Journal of Nuclear Medicine has investigated rhPSMA-10.1, a radiohybrid compound designed to combine PET imaging with targeted alpha therapy for prostate cancer. The approach uses two closely related versions of the same PSMA-targeting molecule: ¹⁸F/La-rhPSMA-10.1 for PET imaging and ²²⁵Ac-rhPSMA-10.1 for treatment. Their similar chemical properties could allow […]

Read more

Doxycycline Shows Preclinical Activity Against Prostate Cancer Bone Metastasis

/in , /by

A new preclinical study suggests that doxycycline, a widely used antibiotic, may help interfere with the process that allows prostate cancer cells to spread and grow in bone. The researchers identified acetylated KLF5 (Ac-KLF5) as an important driver of bone metastasis. This altered form of KLF5 appears to make prostate cancer cells more invasive and […]

Read more

Can One tRNA Reverse Hormone Resistance in Prostate Cancer?

/in /by

A new study published in Nature has identified a single transfer RNA, tRNA1Arg(UCU) as an important regulator of prostate cancer behaviour and resistance to hormone therapy. The researchers found that this tRNA is relatively abundant in androgen receptor-driven prostate cancer, but falls as tumours become more aggressive, more plastic and more neuroendocrine-like. In samples from […]

Read more

Can We Make Metastatic Prostate Cancer Cells Fragile Again?

/in /by

Metastasis requires more than the ability to grow. Tumor cells that enter the bloodstream must also survive powerful mechanical forces that can physically damage or destroy them. A new preclinical study suggests that prostate cancer cells can adapt to this stress, and identifies CALB2 as a possible weak point in that adaptation. Researchers repeatedly exposed […]

Read more

Gallic Acid Targets a New Prostate Cancer Progression Pathway

/in /by

A new preclinical study has identified the NF-κB/KLF7/L1CAM axis as a potential driver of prostate cancer progression and shown that gallic acid can interfere with this pathway. KLF7 was found to promote proliferation, migration and invasion by activating L1CAM, a protein associated with aggressive and metastatic behaviour. Upstream, phosphorylation of the NF-κB p65 subunit appeared […]

Read more

Neuromedin U: A New Way Neuroendocrine Prostate Cancer May Hide From the Immune System

/in /by

Neuroendocrine prostate cancer is one of the most aggressive forms of the disease and remains particularly difficult to treat. A new Oncogene study has identified a possible mechanism that helps these tumours suppress the immune response, centred on a molecule called Neuromedin U, or NMU. In mouse models of neuroendocrine prostate cancer, the researchers found […]

Read more

A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes

/in , /by

CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]

Read more

B7-H3 May Be Doing More Than Marking Prostate Cancer

/in /by

B7-H3 has become one of the most interesting targets in advanced prostate cancer, especially for antibody-drug conjugates and other targeted treatments. A new Cancer Discovery study suggests that B7-H3 may not simply sit on the surface of tumour cells: it may actively help the cancer suppress the immune system and resist treatment. The researchers found […]

Read more

BUB1B and CENP-E: A New Vulnerability in Enzalutamide-Resistant Prostate Cancer

/in /by

A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]

Read more